On Tuesday, New York REIT Inc (NYSE:NYRT)’s shares declined -3.87% to $9.45.
New York REIT Inc (NYRT) declared its financial and operating results for the fourth quarter and year ended December 31, 2014, in addition to results of the first quarter ended March 31, 2015.
Results for the Quarter and Year Ended December 31, 2014:
- Generated Core Funds from Operations (“Core FFO”) of $21.4 million (or $0.13 per fully diluted share) for the fourth quarter, an 8% enhance per share from the third quarter 2014. Core FFO was $80.4 million (or $0.48 per fully diluted share) for the full year 2014.
- Realized Adjusted Funds from Operations (“AFFO”) of $18.0 million (or $0.11 per fully diluted share) for the fourth quarter, which was comparable to the third quarter 2014 on a per share basis. AFFO was $67.0 million (or $0.40 per fully diluted share) for the full year 2014.
- Raised Cash Net Operating Income (“NOI”) to $27.1 million from $26.3 million, an enhance of 3% contrast to the third quarter 2014.
- Stated total occupancy of 94.9% at December 31, 2014, compriseent with the preceding quarter.
- Executed two leases totaling 21,868 square feet during the fourth quarter and 13 leases totaling 142,703 square feet during the full year 2014.
- Raised rental rates on replacement leases by 17% on a cash basis and 42% on a GAAP basis for the fourth quarter and 12% on a cash basis and 19% on a GAAP basis for the full year 2014.
New York REIT, Inc. focuses on acquiring commercial real estate, in addition to acquiring properties or making other real estate investments that relate to office, retail, multi-family residential, industrial, and hotel property types located primarily in New York City.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s shares dropped -3.81% to $1.01.
Lexicon Pharmaceuticals, Inc. (LXRX) declared that the manuscript entitled “Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes” has been selected to present at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 6, 2015, at 9:00 a.m. Eastern Time. The presentation will be part of the 4th Annual Diabetes Care Symposium and will be featured in a special July issue of Diabetes Care. This high-level symposium represents a competition of manuscripts presented to the journal and dedicated to the theme of “Novel Clinical Interventions in Therapy That Impact the Administration of Diabetes.” The manuscript was selected from over 150 manuscripts that were presented for the competition and will be accessible online on June 6, 2015, at care.diabetesjournals.org.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
At the end of Tuesday’s trade, Gap Inc (NYSE:GPS)‘s shares dipped -3.79% to $38.36.
Gap Inc (GPS) stated that April net sales were $1.21 billion for the four-week period ended May 2, 2015, contrast with net sales of $1.33 billion for the four-week period ended May 3, 2014. For the first quarter of fiscal year 2015, Gap Inc.’s net sales reduced 3 percent to $3.66 billion contrast with $3.77 billion for the first quarter last year.
The translation of net sales in foreign currencies into U.S. dollars negatively influenced the company’s stated sales for the first quarter of fiscal year 2015 by about $90 million, primarily due to the weakening Japanese yen and Canadian dollar. On a constant currency basis, net sales for the first quarter of fiscal year 2015 reduced 1 percent contrast with last year. In calculating the net sales change on a constant currency basis, current year foreign exchange rates are applied to both current year and preceding year net sales. This is done to enhance the visibility of underlying sales trends, not taking into account the impact of foreign currency exchange rate fluctuations.
The Gap, Inc. operates as an apparel retail company worldwide. It offers apparel, accessories, and personal care products for men, women, and children under the Gap, Banana Republic, Old Navy, Athleta, and Intermix brand names.
E-House (China) Holdings Limited (ADR) (NYSE:EJ), ended its Tuesday’s trading session with -3.57% loss, and closed at $6.76.
E-House (China) Holdings Limited (ADR) (EJ) declared that it will report its unaudited financial results for the first quarter ended March 31, 2015 before the U.S. markets open on May 19, 2015.
E-House’s administration will host an earnings conference call on May 19, 2015 at 8:15 a.m. U.S. Eastern Time (8:15 p.m. Beijing/Hong Kong time).
E-House (China) Holdings Limited, through its auxiliaries, operates as a real estate services company in the People’s Republic of China. It operates through Real Estate Online Services; Real Estate Brokerage Services; Real Estate Information and Consulting Services; Community Value-Added Services; and Other Services segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
